Drug ID:Drug167
Drug Name:Tilpisertib
CID:124181541
DrugBank ID:DB18798
Modality:Small Molecule
Groups:NULL
US Approved:NO
Other Approved:NO
Identifier: NCT04130919
Molecular Formula:C33H33ClN8O
Molecular Weight:593.1 g/mol
Isomeric SMILES:CC(C)(C)CNC1=C2C=C(C=C(C2=NC=C1C#N)Cl)N[C@@H](C3=CC=CC4=C3C=CN(C4=O)C)C5=CN(N=N5)C67CC(C6)C7
Synonyms:Tilpisertib; 2065153-41-3; UNII-A8Y5K4G762; Tilpisertib [INN]; A8Y5K4G762; GS-4875; 6-[[(S)-[1-(1-bicyclo[1.1.1]pentanyl)triazol-4-yl]-(2-methyl-1-oxoisoquinolin-5-yl)methyl]amino]-8-chloro-4-(2,2-dimethylpropylamino)quinoline-3-carbonitrile; 3-Quinolinecarbonitrile, 6-(((S)-(1-bicyclo(1.1.1)pent-1-yl-1H-1,2,3-triazol-4-yl)(1,2-dihydro-2-methyl-1-oxo-5-isoquinolinyl)methyl)amino)-8-chloro-4-((2,2-dimethylpropyl)amino)-; GS 4875; 6-(((S)-(1-(1-bicyclo(1.1.1)pentanyl)triazol-4-yl)-(2-methyl-1-oxoisoquinolin-5-yl)methyl)amino)-8-chloro-4-(2,2-dimethylpropylamino)quinoline-3-carbonitrile
Phase 0: 0
Phase 1: 0
Phase 2: 1
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1244 124181541 Tilpisertib 1326 MAP3K8 Homo sapiens (human) Inhibitor
dt1245 124181541 Tilpisertib 2199 FBLN2 Homo sapiens (human) Inhibitor
dt1246 124181541 Tilpisertib 1326 MAP3K8 Homo sapiens (human) 33077936 Mitogen-activated protein kinase kinase kinase 8 inhibitor

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT04130919 Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis PHASE2 TERMINATED Gilead Sciences Ulcerative Colitis DRUG: Tilpisertib|DRUG: Placebo Details
NCT06029972 Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis PHASE2 RECRUITING Gilead Sciences Ulcerative Colitis DRUG: Tilpisertib Fosmecarbil|DRUG: Placebo Details
NCT04624230 Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis PHASE3 RECRUITING Pfizer Ulcerative Colitis DRUG: tofacitinib Details
NCT06651281 Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) PHASE3 RECRUITING Merck Sharp & Dohme LLC Crohn Disease|Colitis, Ulcerative DRUG: Tulisokibart|DRUG: Placebo to tulisokibart Details
NCT04985968 The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis PHASE3 TERMINATED InDex Pharmaceuticals Ulcerative Colitis DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… Details
NCT06681181 A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants PHASE1 RECRUITING GlaxoSmithKline Colitis, Ulcerative DRUG: GSK4528287|DRUG: Placebo Details
NCT06353828 Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients PHASE2 ACTIVE_NOT_RECRUITING CannaMore Biotechs Ulcerative Colitis DRUG: CBD, synthetic form|DRUG: Placebo Details
NCT06321887 EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD PHASE3 RECRUITING Liverpool University Hospitals NHS Foundation Trust Inflammatory Bowel Disease|Iron Deficiency Anemia DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… Details
NCT01011322 A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis PHASE2 UNKNOWN Lipid Therapeutics GmbH Ulcerative Colitis|Large Intestine|Diarrhea|Abdom… DRUG: LT-02|DRUG: placebo Details
NCT02610569 Comparison of PillCamCOLON (C2) Capsule and Standard Endoscopy for the Evaluation of Patients With Ulcerative Colitis None COMPLETED Dr. Arnaud Bourreille Ulcerative Colitis DEVICE: standard endoscopy|DEVICE: PillCamCOLON (… Details
NCT06109441 Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics PHASE2 RECRUITING AltruBio Inc. Ulcerative Colitis BIOLOGICAL: ALTB-268 Details
NCT06420492 Study of Novel Therapeutics for Acute Remedy of Colitis PHASE2 NOT_YET_RECRUITING Brigham and Women's Hospital Ulcerative Colitis|Ulcerative Colitis Chronic Mod… DRUG: BRS201 Details
NCT02039505 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis PHASE3 COMPLETED Takeda Ulcerative Colitis DRUG: Vedolizumab|DRUG: Vedolizumab placebo Details
NCT02392221 Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2011). None COMPLETED Centre Hospitalier Universitaire, Amiens Pediatric Inflammatory Bowel Disease None Details
NCT05907330 Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis PHASE2 NOT_YET_RECRUITING Curacle Co., Ltd. Ulcerative Colitis DRUG: CU104|DRUG: Placebo Details
NCT01100112 (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets PHASE3 COMPLETED Bausch Health Americas, Inc. Colitis, Ulcerative DRUG: Budesonide Details
NCT06636656 A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis PHASE2 RECRUITING Boehringer Ingelheim Ulcerative Colitis DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… Details
NCT04996797 A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) PHASE2 ACTIVE_NOT_RECRUITING Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Ulcerative Colitis DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… Details
NCT03832400 Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC) PHASE1 COMPLETED NuBiyota Ulcerative Colitis BIOLOGICAL: MET-2|DRUG: Placebo oral capsule Details
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3 RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations